Loading…
VBIO
Valion Bio, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 888705308
$0.12-1.39%Price as of Aug 29, 18:50 UTC · updated once a day, after the close
Key metrics
- Market cap
- $107.31K
- P/E
- —
- Forward P/E
- —
- P/B
- 0.1x
- Dividend yield
- —
- Payout
- —
- EPS
- -$7.38
- ROE
- -459.52%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.86
- 52-week high
- $3.21
- 52-week low
- $0.11
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $36.25 | $147.05 | $765.00 | $27,200.00 | |
| P/S | — | — | — | 2.2x | 3.4x |
| P/B | 1.0x | 0.2x | 1.3x | 0.7x | 1.7x |
| EPS | -$196.00 | -$492.00 | -$4,420.00 | -$44,475.77 | |
| Profit margin | — | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NXLNexalin Technology, Inc. | $0.25 | — | 3.6x | — | -240.25% | $213.88K |
| GCTKGlucotrack, Inc. | $0.28 | 0.0x | — | — | -620.63% | $225.08K |
| ARTLArtelo Biosciences Inc | $0.66 | — | 0.6x | — | -705.71% | $363.01K |
| VTAKCatheter Precision, Inc. | $0.20 |
About the company
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
- 52
- San Antonio, United States
Company description provided by Yahoo Finance.